LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR NOVO NORDISK INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS
Related Questions
Are there any insider or related party exposures that could be revealed during the lawsuit?
How will the securities fraud lawsuit deadline affect Novo Nordisk's stock price in the short term?
What is the estimated size of the class of affected investors and potential total liability?
Could the lawsuit lead to a material adverse change (MAC) event that triggers a price drop?
How might the legal proceedings impact Novo Nordics's earnings guidance or cash flow forecasts?
What is the likelihood of a settlement versus a court trial, and how would each scenario affect the share price?
How does this legal action compare to recent class actions against other pharmaceutical companies?
Will the lawsuit increase short interest or trigger margin calls among traders holding NVO positions?
What is the potential impact on Novo Nordisk's credit ratings and borrowing costs due to the lawsuit?